Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorSZEIMIES, R. M.-
dc.contributor.authorTOREZAN, L.-
dc.contributor.authorNIWA, A.-
dc.contributor.authorVALENTE, N.-
dc.contributor.authorUNGER, P.-
dc.contributor.authorKOHL, E.-
dc.contributor.authorSCHREML, S.-
dc.contributor.authorBABILAS, P.-
dc.contributor.authorKARRER, S.-
dc.contributor.authorFESTA-NETO, C.-
dc.identifier.citationBRITISH JOURNAL OF DERMATOLOGY, v.167, n.1, p.150-159, 2012-
dc.description.abstractBackground The field cancerization concept in photodamaged patients suggests that the entire sun-exposed surface of the skin has an increased risk for the development of (pre)-malignant lesions, mainly epithelial tumours. Topical photodynamic therapy (PDT) is a noninvasive therapeutic method for multiple actinic keratosis (AK) with excellent outcome. Objectives To evaluate the clinical, histological and immunohistochemical changes in human skin with field cancerization after multiple sessions of PDT with methyl-aminolaevulinate (MAL). Methods Twenty-six patients with photodamaged skin and multiple AK on the face received three consecutive sessions of MAL-PDT with red light (37 J cm(-2)), 1 month apart. Biopsies before and 3 months after the last treatment session were taken from normal-appearing skin on the field-cancerized area. Immunohistochemical stainings were performed for TP-53, procollagen-I, metalloproteinase-1 (MMP-1) and tenascin-C (Tn-C). Results All 26 patients completed the study. The global score for photodamage improved considerably in all patients (P < 0.001). The AK clearance rate was 89.5% at the end of the study. Two treatment sessions were as effective as three MAL-PDT sessions. A significant decrease in atypia grade and extent of keratinocyte atypia was observed histologically (P < 0.001). Also, a significant increase in collagen deposition (P = 0.001) and improvement of solar elastosis (P = 0.002) were noticed after PDT. However, immunohistochemistry showed only a trend for decreased TP-53 expression (not significant), increased procollagen-I and MMP-1 expressions (not significant) and an increased expression of Tn-C (P = 0.024). Conclusions Clinical and histological improvement in field cancerization after multiple sessions of MAL-PDT is proven. The decrease in severity and extent of keratinocyte atypia associated with a decreased expression of TP-53 suggest a reduced carcinogenic potential of the sun-damaged area. The significant increase of new collagen deposition and the reduction of solar elastosis explain the clinical improvement of photodamaged skin.-
dc.relation.ispartofBritish Journal of Dermatology-
dc.subject.otherhuman epidermal-keratinocytes-
dc.subject.othersquamous-cell carcinoma-
dc.subject.otherintense pulsed-light-
dc.subject.other5-aminolevulinic acid-
dc.subject.otheractinic keratoses-
dc.subject.othermatrix metalloproteinases-
dc.subject.othertransplant recipients-
dc.subject.othertopical application-
dc.titleClinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy-
dc.rights.holderCopyright WILEY-BLACKWELL-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-, R. M.:Regensburg Univ Hosp, Dept Dermatol, Regensburg, Germany-, A.:Univ Sao Paulo, Hosp Clin, Dept Dermatol, Sao Paulo, Brazil-, P.:Regensburg Univ Hosp, Dept Dermatol, Regensburg, Germany-, E.:Regensburg Univ Hosp, Dept Dermatol, Regensburg, Germany-, S.:Regensburg Univ Hosp, Dept Dermatol, Regensburg, Germany-, P.:Regensburg Univ Hosp, Dept Dermatol, Regensburg, Germany-, S.:Regensburg Univ Hosp, Dept Dermatol, Regensburg, Germany-
hcfmusp.relation.referenceAlexiades-Armenakas MR, 2003, ARCH DERMATOL, V139, P1313, DOI 10.1001/archderm.139.10.1313-
hcfmusp.relation.referenceApalla Z, 2010, BRIT J DERMATOL, V162, P171, DOI 10.1111/j.1365-2133.2009.09492.x-
hcfmusp.relation.referenceAvram D, 2004, J DRUGS DERMATOL, V3, P36-
hcfmusp.relation.referenceBabilas P, 2003, Hautarzt, V54, P551-
hcfmusp.relation.referenceBagazgoitia L, 2011, BRIT J DERMATOL, V165, P144, DOI 10.1111/j.1365-2133.2011.10270.x-
hcfmusp.relation.referenceBerg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274-
hcfmusp.relation.referenceBissonnette R, 2007, DERMATOL CLIN, V25, P95, DOI 10.1016/j.det.2006.09.011-
hcfmusp.relation.referenceBraakhuis BJM, 2003, CANCER RES, V63, P1727-
hcfmusp.relation.referenceBraathen LR, 2007, J AM ACAD DERMATOL, V56, P125, DOI 10.1016/j.jaad.2006.06.006-
hcfmusp.relation.referenceBraathen LR, 2008, J EUR ACAD DERMATOL, V23, P550-
hcfmusp.relation.referenceChoi JY, 2010, J DERMATOL SCI, V58, P198, DOI 10.1016/j.jdermsci.2010.03.019-
hcfmusp.relation.referenceDang C, 2006, BRIT J DERMATOL, V155, P763, DOI 10.1111/j.1365-2133.2006.07401.x-
hcfmusp.relation.referenceDover JS, 2005, ARCH DERMATOL, V141, P1247, DOI 10.1001/archderm.141.10.1247-
hcfmusp.relation.referenceFink-Puches R, 1998, ARCH DERMATOL, V134, P821, DOI 10.1001/archderm.134.7.821-
hcfmusp.relation.referenceGold MH, 2006, DERMATOL SURG, V32, P795, DOI 10.1111/j.1524-4725.2006.32163.x-
hcfmusp.relation.referenceIssa MCA, 2009, BRIT J DERMATOL, V161, P647, DOI 10.1111/j.1365-2133.2009.09326.x-
hcfmusp.relation.referenceKarrer S, 2003, J INVEST DERMATOL, V120, P325, DOI 10.1046/j.1523-1747.2003.12037.x-
hcfmusp.relation.referenceKarrer S, 2004, BRIT J DERMATOL, V151, P776, DOI 10.1111/j.1365-2133.2004.06209.x-
hcfmusp.relation.referenceKleinpenning MM, 2010, J DERMATOL TREAT, V21, P252, DOI 10.3109/09546630903271555-
hcfmusp.relation.referenceKohl E, 2011, J EUR ACAD DERMATOL, V25, P873, DOI 10.1111/j.1468-3083.2010.03963.x-
hcfmusp.relation.referenceKohl E, 2010, J EUR ACAD DERMATOL, V24, P1-
hcfmusp.relation.referenceLatijnhouwers M, 1997, J INVEST DERMATOL, V108, P776, DOI 10.1111/1523-1747.ep12292170-
hcfmusp.relation.referenceLatijnhouwers MAHE, 1998, MATRIX BIOL, V17, P305, DOI 10.1016/S0945-053X(98)90083-X-
hcfmusp.relation.referenceMARKS R, 1988, LANCET, V1, P795-
hcfmusp.relation.referenceMarmur Ellen S, 2005, J Cosmet Laser Ther, V7, P21, DOI 10.1080/147641700510037725-
hcfmusp.relation.referenceMcCarthy M, 2005, J AM COLL SURGEONS, V201, P245, DOI 10.1016/j.jamcollsurg.2005.03.034-
hcfmusp.relation.referenceOrringer JS, 2008, ARCH DERMATOL, V144, P1296, DOI 10.1001/archderm.144.10.1296-
hcfmusp.relation.referenceOrringer JS, 2004, ARCH DERMATOL, V140, P1073, DOI 10.1001/archderm.140.9.1073-
hcfmusp.relation.referencePark MY, 2010, J AM ACAD DERMATOL, V62, P85, DOI 10.1016/j.jaad.2009.06.025-
hcfmusp.relation.referenceQuan TH, 2004, AM J PATHOL, V165, P741, DOI 10.1016/S0002-9440(10)63337-8-
hcfmusp.relation.referenceSharfaei S, 2002, ARCH DERMATOL RES, V294, P237, DOI 10.1007/s00403-002-0320-4-
hcfmusp.relation.referenceSLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q-
hcfmusp.relation.referenceSzeimies RM, 1996, DERMATOLOGY, V192, P246-
hcfmusp.relation.referenceTouma D, 2004, ARCH DERMATOL, V140, P33, DOI 10.1001/archderm.140.1.33-
hcfmusp.relation.referenceWennberg AM, 2008, TRANSPLANTATION, V86, P423, DOI 10.1097/TP.0b013e318180731e-
hcfmusp.relation.referenceWulf HC, 2006, ACTA DERM-VENEREOL, V86, P25, DOI 10.1080/00015550510042868-
hcfmusp.relation.referenceZane C, 2007, LASER SURG MED, V39, P203, DOI 10.1002/lsm.20470-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MDT
Departamento de Dermatologia - FM/MDT

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/53
LIM/53 - Laboratório de Micologia

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)685.3 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.